Reply to letter on results of NRG Oncology RTOG 9813

<span class="paragraphSection">We appreciate the insightful comments of the reader. We agree that it would have been ideal to publish isocitrate dehydrogenase (IDH) data inclusive of mutational and immunohistochemical (IHC) data concurrently. However, the reality was that tissue submission was not mandatory in RTOG 9813 in its original draft. Therefore, the Principal Investigators had to resort to retrospective collection of unstained slides and tissue blocks from participating institutions, where still available. As one would expect, our initial success was in the collection of the former, which we could utilize for IHC for IDH. The tissue blocks have required more time to collect. Since the clinical data were mature for publication, the investigators decided to proceed with publication of these important data inclusive of available IHC data for IDH. Our plan is to generate a subsequent publication inclusive of IDH sequencing data once tissue blocks have been received from participating institutions. Much like the reader, we are eager to learn of these results.</span>

http://ift.tt/2qozsho